Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. BOIRON
  6. News
  7. Summary
    BOI   FR0000061129

BOIRON

(BOI)
  Report
Real-time Euronext Paris  -  11:35 2022-09-28 am EDT
44.00 EUR    0.00%
09/15Boiron SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
09/15BOIRON : Half-year report
CO
09/08Boiron : 2022 half-year results
AN
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Boiron : 2022 first quarter sales

04/22/2022 | 05:05am EDT

(Unaudited data)














In thousands of euros 2022 2021 Variation at current
exchange rates
Variation at constant
exchange rates
France 77,055 51,518 +49.6% +49.6%
Europe (excluding France) 34,476 20,039 +72.0% +74.2%
North America 28,944 17,657 +63.9% +52.6%
Other countries 5,305 1,958 +171.0% +160.0%
Group total 145,780 91,172 +59.9% +58.0%

 

In thousands of euros 2022 2021 Variation at current
exchange rates
Variation at
constant
exchange rates
Non-proprietary Homeopathic Medicines 45,516 46,352 -1.8% -2.8%
Homeopathic Specialties 67,100 39,430 +70.2% +67.0%
Other health products* 33,164 5,390 +515.3% +514.6%
Group total 145,780 91,172 +59.9% +58.0%

* “Other healthcare products” include the non-homeopathic products (medical devices, nutritional supplements, cosmetics, phytotherapy) that were previously listed in the “OTC specialty” section.

Changes in turnover

During the 1st quarter of 2022, turnover increased sharply across all geographic regions due to:

  • the base effect created by the steep drop in turnover during the 1st quarter of 2021 (-41.8%) due to the pandemic,
  • growth in homeopathic specialty medicines,
  • growth in other healthcare products, particularly COVID tests, which were not yet on the market in France during the 1st quarter of 2021,
  • our continued strategy of innovation, particularly with the launch of Varésol®, a new homeopathic medicine indicated for chickenpox symptoms, during the first quarter of this year.

Outlook

The Group's sales may be affected by the current geopolitical situation. We are closely monitoring the situation and its impact as they develop and are taking all the necessary measures for the organization of our activities.

However, we do anticipate increased turnover in 2022 and we continue to put all our energy and determination into the promotion of homeopathy in France and around the world.

Laboratoires BOIRON


Our next updates:
The Ordinary Shareholders' Meeting will be held on May 19, 2022 at 10:30 am, at BOIRON headquarters, 2 avenue de l'Ouest Lyonnais, 69510 MESSIMY – FRANCE.
June 3, 2022: after approval by the Ordinary Shareholders' Meeting, payment of the proposed dividend (€0.95 per share).
July 21, 2022: after the close of the stock market, publication of the sales on June 30, 2022.
Person responsible for financial information: Valérie Lorentz-Poinsot
Contact for financial information: Fabrice Rey
Investor relations: +33 (0) 4.37.41.84.01 - e-mail: boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at : www.boironfinance.com



This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: x5uclZeXZWeYnGmcZ5puaWdjnJySyGmWZmjGlmabYpqacJyVlW+WapaeZnBllW5v
- Check this key: https://www.security-master-key.com.



Regulated information:
Quarterly financial reporting:
- First quarter financial report


Full and original press release in PDF: https://www.actusnews.com/news/74099-boi-210422-ca-t1-2022-gb.pdf

Receive by email the next press releases of the company by registering on www.actusnews.com, it's free


© 2022 ActusNews
All news about BOIRON
09/15Boiron SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
09/15BOIRON : Half-year report
CO
09/08Boiron : 2022 half-year results
AN
09/07BOIRON : 1st-half-year results
CO
07/27Boiron : Projected timetable of the next publications and events 2023
AN
07/27BOIRON : Provisional calendar
CO
07/21BOIRON : 2nd quarter earnings
CO
06/29Global markets live: Novartis, Tesla, Disney, Sony, Walmart...
MS
06/29Galenica's Verfora To Take Over Distribution Of Boiron Products In Switzerland
MT
06/29Press Release : BOIRON Laboratories, the world leader in homeopathy, has entrusted the dis..
PU
More news
Financials
Sales 2022 514 M 496 M 496 M
Net income 2022 49,1 M 47,4 M 47,4 M
Net cash 2022 267 M 257 M 257 M
P/E ratio 2022 17,1x
Yield 2022 2,61%
Capitalization 764 M 734 M 737 M
EV / Sales 2022 0,97x
EV / Sales 2023 0,87x
Nbr of Employees 2 794
Free-Float 24,3%
Chart BOIRON
Duration : Period :
BOIRON Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BOIRON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 44,00 €
Average target price 53,33 €
Spread / Average Target 21,2%
EPS Revisions
Managers and Directors
Valérie Lorentz-Poinsot Chief Executive Officer & Director
Thierry Boiron Chairman
Hervé Coulpier Director-Information Technology Services
Isabelle Chanel Research & Development Medical
Patrice Varraut Operations Director & Sales Director